谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Durvalumab with or Without Tremelimumab in Combination with Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

Solange Peters,Byoung Chul Cho,Alexander V. Luft,Jorge Alatorre-Alexander,Sarayut Lucien Geater,Konstantin Laktionov,Dmytro Trukhin,Sang-We Kim, Grygorii M. Ursol,Maen Hussein,Farah Louise Lim,Cheng-Ta Yang,Luiz Henrique Araujo,Haruhiro Saito,Niels Reinmuth, Caitlin Lowery,Helen Mann,Ross Stewart,Haiyi Jiang,Edward B. Garon,Tony Mok, Melissa L. Johnson

JOURNAL OF THORACIC ONCOLOGY（2025）

引用 1|浏览12
关键词
Tremelimumab,Durvalumab,POSEIDON,Meta- static NSCLC,Five-year overall survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要